Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
Thursday, August 27, 2020 4:16:14 PM
OCALA, FL / ACCESSWIRE / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show t...
Read the whole news AIM - AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19
Recent AIM News
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs • GlobeNewswire Inc. • 04/15/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/11/2024 03:00:00 PM
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer • GlobeNewswire Inc. • 04/10/2024 12:21:00 PM
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:05:00 PM
- AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 03/26/2024 01:05:00 PM
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 03/25/2024 01:05:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/22/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/20/2024 01:25:00 PM
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity • GlobeNewswire Inc. • 03/15/2024 12:45:00 PM
- AIM ImmunoTech Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 03/07/2024 01:45:00 PM
- AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 01:45:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 02/21/2024 03:37:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:31:03 PM
- AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 02/14/2024 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 08:47:35 PM
- AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions • GlobeNewswire Inc. • 02/08/2024 01:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:00:16 PM
- AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer • GlobeNewswire Inc. • 01/24/2024 02:10:00 PM
- AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 01/22/2024 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 06:42:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:45:12 PM
- AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 01/10/2024 01:45:00 PM
- AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting • Business Wire • 01/05/2024 06:32:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM